

## Technology Advisory Committee C Interests Register

### Topic Acalabrutinib for untreated and treated chronic lymphocytic leukaemia [ID1613]

Publication Date: 21/04/2021

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Michael Chambers	Committee Member	Financial	Michael is currently helping to co-ordinate a training programme on Real World Evidence for Roche pharmaceuticals (manufacturer of a potential comparator): this has not involved specific consideration of any Roche products.	01.10.2020	05.11.2020 09.02.2021	N/A	It was agreed that this declaration would not prevent Michael from participating in discussions on this appraisal.
Dr Prithwiraj Das	Committee Member	Non-financial professional & personal	Prithwiraj works at the pharmaceutical company Boehringer Ingelheim Ltd as the Market Access Lead for Specialty Therapies. He has not worked in the indication under consideration in the last twelve months.	07.10.2020	05.11.2020	N/A	It was agreed that this declaration would not prevent Prithwiraj from participating in discussions on this appraisal.
Dr Richard Nicholas	Committee Member	Non-financial professional & personal	Richard has been a PI on trials and attended paid advisory boards for Roche and Novartis in an unrelated area.	07.10.2020	05.11.2020 09.02.2021	N/A	It was agreed that this declaration would not prevent Richard from participating in

							discussions on this appraisal.
Professor Matthew Stevenson	Committee Member	Non-financial professional & personal	Matthew works for the ERG ScHARR. He was not involved in drafting the ERG report.	02.10.2020	05.11.2020 09.02.2021	N/A	It was agreed that this declaration would not prevent Matthew from participating in discussions on this appraisal.
Professor Adrian Bloor	Clinical expert	Financial	Adrian has attended advisory boards and has received conference and speaker funding from Novartis, Gilead, AbbVie and Janssen all within the last five years and he is also the medical lead for the Doctors Laboratory Manchester Hub.	15.05.2020	05.11.2020 09.02.2021	N/A	It was agreed that this declaration would not prevent Adrian from providing expert advice on this appraisal.
Professor Anna Schuh	Clinical expert	Financial	Anna has received honoraria for giving education talks from Abbvie, Roche, Janssen and Gilead all within the last two years and is a PI on the Abbvie study M13-982 which was the study evaluating venetoclax in patients with del17 CLL.	01.06.2020	05.11.2020 09.02.2021	N/A	It was agreed that this declaration would not prevent Anna from providing expert advice on this appraisal.
Nick York	Patient expert	Financial	Nick is an employee of Leukaemia Care and the Chair of the CLL Advocates Network (CLLAN), which also	05.06.2020	05.11.2020 09.02.2021	N/A	It was agreed that this declaration would not prevent Nick from providing expert

			receives funding from pharmaceutical companies.				advice on this appraisal.
Jackie Martin	Patient expert	Financial	Jackie is a patient with CLL undergoing treatment with ibrutinib as a participant in the FLAIR clinical trial. She is also an administrator for the online CLL patient forum on the Health Unlocked platform and a patient advocate which also receive funding from pharmaceutical companies.	04.06.2020	05.11.2020	N/A	It was agreed that this declaration would not prevent Jackie from providing expert advice on this appraisal.